Tablets, drops and sublingual “tirzepatide” are unapprovedAnything sold as a tirzepatide pill, tablet, drop or under-the-tongue product is not an FDA-approved medicine. The FDA says compounded drugs “are not FDA approved” and are not reviewed for safety, effectiveness or quality before they are sold.[6]
Is there an oral tirzepatide?
No. Drugs@FDA lists two tirzepatide applications, Mounjaro and Zepbound, and every product under them is a solution for subcutaneous injection: pens, vials and KwikPens.[2][1] The Zepbound label is titled “ZEPBOUND (tirzepatide) injection, for subcutaneous use.”[3]
| Brand | Route | Forms | Approved for |
|---|---|---|---|
| Mounjaro | Injection under the skin | Pen, vials, KwikPen | Type 2 diabetes; cardiovascular risk in type 2 diabetes |
| Zepbound | Injection under the skin | Pen, vials, KwikPen | Weight management; obstructive sleep apnea |
| Any tirzepatide tablet, capsule, drop or film | — | — | Not approved |
A search of ClinicalTrials.gov for oral, tablet or sublingual tirzepatide found no registered study of an oral tirzepatide formulation, including among Lilly's 82 tirzepatide trials.[4] That does not prove no internal research exists, but no oral tirzepatide is in public clinical testing.
Tirzepatide tablets and sublingual products
Tirzepatide tablets, drops and sublingual products come from compounders or unapproved sellers, not from the manufacturer. In its December 2024 review of the tirzepatide shortage, the FDA noted information that “some compounders are preparing tirzepatide drug products in oral and sublingual dosage forms.”[5]
- The FDA says compounded drugs are not reviewed for safety, effectiveness or quality before they are marketed.[6]
- It has warned companies selling tirzepatide labeled “for research purposes” or “not for human consumption.”[6]
- Lilly states that Mounjaro and Zepbound are approved only for under-the-skin injection, and that some telehealth providers and compounders market pill, sublingual and nasal-spray “tirzepatide.”[7]
Background on the legal status is on compounded tirzepatide, and on how compounded products differ from the approved one on compounded tirzepatide vs Zepbound.
Why a tirzepatide pill is hard to make
Tirzepatide is a large peptide, and large peptides are poorly absorbed from the gut; the approved peptide pill, oral semaglutide, needs an absorption enhancer and still absorbs about 1% or less.[13] The label numbers show the gap:
| Drug | Type | Route | Molecular weight | Bioavailability |
|---|---|---|---|---|
| Tirzepatide (Zepbound, Mounjaro)[3] | Peptide | Injection | 4,813.53 Da | 80% |
| Semaglutide tablets (Rybelsus)[13] | Peptide + SNAC enhancer | Oral | — | About 0.4–1% |
| Orforglipron (Foundayo)[9] | Small molecule, non-peptide | Oral | 902.0 g/mol | 77% |
No primary source we found says tirzepatide can never be given by mouth; the point is that a peptide pill needs special formulation and testing, and none has been approved for tirzepatide.
The approved GLP-1 pills: is there a Zepbound pill?
There is no Zepbound pill; the approved weight-loss pills are orforglipron (Foundayo) from Lilly and oral semaglutide (Wegovy tablets) from Novo Nordisk.[8][12]
| Product | Drug | Approved | Dosing | Trial weight change |
|---|---|---|---|---|
| Foundayo[9] | Orforglipron | April 1, 2026 (weight management) | Once daily, 0.8–17.2 mg tablets | −7.5% to −11.2% vs −2.1% (72 weeks)[10] |
| Wegovy tablets[11] | Semaglutide | December 22, 2025 | Once daily, 1.5 mg rising to 25 mg | −13.6% vs −2.4% (64 weeks) |
| Rybelsus[13] | Semaglutide | September 20, 2019 | Once daily | Type 2 diabetes only |
| Zepbound injection[14] | Tirzepatide | November 8, 2023 | Once weekly, 2.5–15 mg | −20.9% at 15 mg vs −3.1% (72 weeks) |
Foundayo is not a pill form of tirzepatide: the FDA describes it as a GLP-1 receptor agonist, while tirzepatide acts on both GIP and GLP-1 receptors.[8][3] As of November 2026 its label approves it for weight management only.[9]
If you have been offered tirzepatide pills
A tirzepatide pill, drop or sublingual product is, by definition, not an FDA-approved medicine, and its dose, purity and absorption have not been reviewed.[6] The approved options for tirzepatide are the injections described on this site: the Zepbound vial, the KwikPen and the single-dose pen. Whether an approved pill such as Foundayo or Wegovy tablets suits a person is a prescriber's decision.
Related
- Zepbound vs WegovyIncluding the Wegovy pill
- Microdosing tirzepatideWhat the evidence shows
- Compounded tirzepatideFDA status and warning letters
Frequently asked questions
Is there a tirzepatide pill?
Is Zepbound available as a pill?
No. Lilly's approved weight-loss pill is Foundayo (orforglipron), a different drug approved on April 1, 2026.[8]
Are tirzepatide tablets FDA-approved?
Sources
- Drugs@FDA: NDA 217806 (Zepbound) approval history and supplement letters
- Drugs@FDA: NDA 215866 (Mounjaro) approval history and supplement letters
- Zepbound (tirzepatide) injection: prescribing information, Medication Guide and Instructions for Use
- ClinicalTrials.gov searches for oral, tablet and sublingual tirzepatide
- Resolution of tirzepatide injection product shortage and supply status (CDER memo, footnote 119)
- FDA's concerns with unapproved GLP-1 drugs used for weight loss
- Protect yourself from counterfeit and unsafe, mass compounded products
- FDA approves first new molecular entity under National Priority Voucher program (Foundayo)
- Foundayo (orforglipron) tablets: prescribing information
- Wharton S et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1)
- Wegovy (semaglutide) injection and tablets: prescribing information
- NDA 218316 approval letter: Wegovy tablets
- Rybelsus (semaglutide) tablets: prescribing information
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)